Restless Leg Syndrome (RLS) Treatment — Evidence-Based Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Restless Leg Syndrome (RLS), also known as Willis-Ekbom Disease (WED), is a neurological sensorimotor disorder characterised by an irresistible urge to move the legs, typically accompanied by uncomfortable or unpleasant sensations. It affects 5–10% of adults in Western populations, with a 2:1 female predominance, and is among the most common causes of chronic sleep disturbance.

The International Restless Legs Syndrome Study Group (IRLSSG) 2022 diagnostic criteria require all five of the following to be present:

• An urge to move the legs, usually accompanied by uncomfortable sensations
• Symptoms begin or worsen during periods of rest or inactivity
• Symptoms are partially or totally relieved by movement (walking, stretching)
• Symptoms are worse in the evening or night compared to the day
• The above features are not solely accounted for by another medical condition or a behavioural disorder

Augmented by validated tools such as the IRLSSG Rating Scale (IRLS), clinicians can quantify symptom severity from mild (1–10) to very severe (31–40), guiding treatment decisions. RLS impairs sleep onset and maintenance, reduces daytime functioning, and is associated with significant cardiovascular and psychiatric comorbidity. Accurate diagnosis, exclusion of mimics (peripheral neuropathy, positional discomfort, PLMD), and identification of secondary causes are essential before initiating pharmacotherapy.

RLS is broadly classified as primary (idiopathic) or secondary (symptomatic). Differentiating these forms directs management strategy:

• Primary RLS: Strong familial clustering; associated with variants in BTBD9, MEIS1, MAP2K5, and PTPRD genes. Dopaminergic and iron dysregulation in the central nervous system (particularly substantia nigra) are implicated. Onset typically before age 45.
• Iron deficiency and anaemia: Serum ferritin <75 µg/L correlates with RLS severity; iron is a cofactor for tyrosine hydroxylase in dopamine synthesis. IV iron is first-line in iron-deficient cases.
• Pregnancy: RLS occurs in up to 26% of pregnancies, especially the third trimester; iron and folate deficiency contribute. Symptoms typically resolve post-partum.
• Chronic kidney disease (CKD): Dialysis patients have RLS prevalence of 20–40%; uraemic toxins and iron deficiency are key drivers.
• Peripheral neuropathy: Dysaesthesias can mimic RLS; nerve conduction studies help exclude this mimic.
• Medications that worsen RLS: Dopamine antagonists (antipsychotics, metoclopramide), antihistamines (diphenhydramine), SSRIs/SNRIs, and lithium can precipitate or aggravate RLS and should be reviewed in every patient.

Secondary causes should be corrected before or alongside pharmacotherapy for optimal outcomes.

Not all patients with RLS require pharmacological treatment. Eligibility is determined by symptom frequency, severity, and impact on quality of life:

• Mild/infrequent RLS (IRLS <11, <2 nights/week): Non-pharmacological measures are appropriate first-line therapy.
• Moderate-to-severe RLS (IRLS ≥11, ≥3 nights/week): Pharmacotherapy is indicated after ruling out secondary causes.

Pre-treatment investigations should include:

• Serum ferritin and transferrin saturation (TSAT) — ferritin <75 µg/L or TSAT <20% prompts iron supplementation
• Complete blood count, renal function, thyroid function, fasting glucose
• Medication review (identify culprit drugs)
• Polysomnography if periodic limb movements in sleep (PLMS) or sleep apnoea are suspected
• Nerve conduction studies if neuropathy is suspected

Pregnancy considerations: Most dopaminergic agents are avoided in pregnancy; low-dose clonazepam or low-molecular weight heparin may be used. Iron supplementation is safe and indicated. Pregabalin is teratogenic (Category D) and contraindicated.

Augmentation risk stratification: Patients with severe baseline RLS, early symptom onset, family history, or low ferritin are at higher risk of augmentation on dopamine agonists and may be better suited for alpha-2-delta ligands as first-line therapy.

Treatment is individualised based on RLS severity, secondary cause, augmentation risk, and comorbidities. Current evidence-based options include:

1. Intravenous Iron Therapy

• Indicated when ferritin <75 µg/L, per IRLSSG guidelines. IV iron sucrose or low-molecular-weight iron dextran (LMWID) are preferred formulations.
• A single infusion of LMWID 1,000 mg can sustain ferritin levels for months and reduce IRLS score by 4–8 points.
• Oral iron is less effective due to gastrointestinal absorption variability; IV iron is preferred in moderate-to-severe RLS with iron deficiency.

2. Dopamine Agonists (DA)

• Pramipexole (0.125–0.5 mg nightly), ropinirole (0.25–4 mg nightly), and rotigotine transdermal patch (1–3 mg/24h) are FDA-approved for moderate-to-severe RLS.
• Low doses are strongly recommended to minimise augmentation risk — the most important long-term complication of DA therapy. Augmentation manifests as earlier symptom onset, spread to arms or trunk, and increased severity despite dose escalation.
• Impulse control disorders (ICDs: gambling, hypersexuality) occur in up to 17% of patients on DAs and require vigilant monitoring.

3. Alpha-2-Delta Calcium Channel Ligands

• Pregabalin (75–300 mg nightly) and gabapentin enacarbil (600 mg nightly) are preferred alternatives, particularly for patients at high augmentation risk or those who have developed augmentation on DAs.
• The EXPRESS trial (Lancet 2014) found pregabalin non-inferior to pramipexole for RLS symptom control with a significantly lower augmentation rate at 52 weeks (2.1% vs 7.7%).
• Beneficial co-effects include anxiolysis and improved sleep architecture. Use cautiously in elderly patients (fall risk, cognitive effects).

4. Opioids for Refractory RLS

• The RLS-II trial (Lancet Neurology 2013) demonstrated that prolonged-release oxycodone-naloxone (5/2.5–40/20 mg daily) significantly reduced IRLS scores vs. placebo in patients with augmentation or treatment-refractory RLS.
• Low-dose methadone is an alternative for severe refractory cases under specialist supervision.
• Opioids carry dependency and respiratory depression risks and are reserved for carefully selected patients unresponsive to other agents.

Effective RLS treatment delivers benefits across multiple domains of health and well-being:

• Symptom relief: All approved pharmacological agents achieve clinically meaningful reductions in IRLS scores. Dopamine agonists reduce IRLS by 8–12 points on average; pregabalin achieves comparable reductions with favourable long-term tolerability.
• Sleep quality improvement: Patients experience significant improvements in sleep onset latency, total sleep time, and subjective sleep quality. Pregabalin specifically improves slow-wave sleep architecture, which is particularly disrupted in RLS.
• Daytime functioning: Reduced nocturnal awakenings translate to improved daytime alertness, cognitive performance, and occupational productivity.
• Mental health outcomes: RLS is strongly associated with depression and anxiety. Effective RLS control reduces comorbid mood symptoms, with some studies showing up to 30% improvement in depression scores.
• Cardiovascular risk reduction: Chronic sleep deprivation from untreated RLS is associated with increased cardiovascular risk. Normalising sleep with RLS treatment may mitigate this risk.
• Iron therapy benefits: IV iron addresses the root cause in iron-deficient patients, providing durable improvement without the augmentation or ICD risks of dopaminergic agents. It also corrects systemic iron deficiency with broader health benefits.
• Quality of life: Validated QoL instruments (SF-36, RLS-QoL) consistently show significant improvements in physical, emotional, and social functioning following effective treatment.

All RLS treatments carry potential risks that must be weighed against benefits and discussed with patients:

Dopamine Agonists

• Augmentation: The most clinically significant long-term adverse effect of DA therapy. Risk increases with duration of use, higher doses, lower ferritin, and severity of baseline RLS. Management involves optimising iron stores, reducing DA dose, switching to an alpha-2-delta ligand, or adding an opioid.
• Impulse control disorders (ICDs): Pathological gambling, compulsive eating, hypersexuality, and compulsive shopping affect up to 17% of patients. Patients and caregivers must be counselled prior to initiation.
• Rebound and early-morning symptoms: Occur as drug levels fall in the early morning.
• Nausea, dizziness, somnolence, orthostatic hypotension: Common early adverse effects, particularly with dose escalation.

Alpha-2-Delta Ligands

• Dizziness, somnolence, weight gain, peripheral oedema, and cognitive impairment (particularly in older adults)
• Misuse potential with gabapentinoids in patients with substance use history
• Pregabalin is teratogenic and requires effective contraception in women of childbearing age

Opioids

• Physical dependence, constipation, respiratory depression, and overdose risk
• Naloxone component in oxycodone-naloxone mitigates opioid-induced constipation and may reduce misuse potential

IV Iron

• Rare but serious risk of anaphylactoid reactions (1:200,000); infusion must be administered in a setting with resuscitation capability
• Iron overload risk if ferritin is not monitored post-infusion

RLS is often a lifelong condition requiring structured long-term monitoring to ensure treatment efficacy, detect complications, and adjust therapy:

• Initial follow-up: Review at 4–8 weeks after starting pharmacotherapy to assess IRLS score change, tolerability, and adverse effects.
• Augmentation surveillance: At every visit, clinicians should screen for earlier symptom onset, spread to arms or trunk, paradoxical worsening with dose increase, and shorter duration of therapeutic effect — all signs of augmentation on dopamine agonists.
• Ferritin monitoring: Recheck serum ferritin every 3–6 months in patients receiving iron therapy. Target ferritin >75 µg/L (optimally 100–150 µg/L). IV iron re-infusion is indicated if ferritin falls below the threshold with symptom recurrence.
• ICD screening: Patients on dopamine agonists should be screened at every visit for impulse control behaviours using validated questionnaires (e.g., the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease, adapted for RLS).
• Sleep study: Polysomnography is recommended if residual sleep disruption persists despite adequate RLS control, to exclude co-existing obstructive sleep apnoea or PLMD requiring separate treatment.
• Secondary cause re-evaluation: In patients with CKD, periodically reassess renal function and adjust dosing (pregabalin and gabapentin require dose reduction in renal impairment). In post-partum patients, reassess whether treatment is still required as RLS may resolve.

The cost of RLS treatment varies considerably by drug choice, treatment setting, and healthcare system:

• Generic dopamine agonists: Generic pramipexole and ropinirole are widely available at low cost (under USD 20/month in many markets), making them economically accessible first-line options.
• Rotigotine patch: Branded transdermal formulations are significantly more expensive (USD 150–400/month) but offer continuous drug delivery, which may reduce rebound symptoms.
• Pregabalin and gabapentin: Generic pregabalin is available at moderate cost (USD 15–50/month); gabapentin enacarbil (Horizant) remains branded in most markets at higher cost.
• IV Iron infusions: A single infusion of low-molecular-weight iron dextran (1,000 mg) costs USD 300–1,200 depending on facility and formulation. The durable response (often 3–6 months or longer) can make this cost-effective versus daily medications.
• Prolonged-release oxycodone-naloxone: Expensive at USD 300–600/month in markets where available; restricted to specialist prescribing in most countries.
• Specialist consultation: Neurologist or sleep medicine specialist evaluation adds USD 150–400 per visit; often required for refractory cases or augmentation management.
• Sleep studies: Polysomnography costs USD 1,000–3,500 in hospital settings; home sleep testing is cheaper but has limited utility in RLS evaluation.

Medical tourism offers access to expert sleep neurology consultation and IV iron therapy at significantly reduced costs in countries such as India, Thailand, and Germany.

Non-pharmacological strategies are recommended as adjuncts or first-line therapy for mild RLS, and as complementary measures for all severity grades:

• Sleep hygiene optimisation: Consistent sleep-wake schedule, avoiding caffeine and alcohol after midday, and limiting screen exposure before bed reduce RLS trigger exposure and improve overall sleep quality.
• Regular moderate aerobic exercise: Three to four sessions per week of moderate-intensity exercise (walking, cycling) have been shown in randomised trials to reduce IRLS scores by 3–6 points, comparable to low-dose pharmacotherapy in mild cases.
• Hot or cold baths before bedtime: Temperature modulation of the legs temporarily relieves RLS symptoms through peripheral sensory mechanisms.
• Leg massage and stretching: Calf and hamstring stretching exercises and self-massage before sleep can reduce the urgency to move and delay symptom onset.
• Pneumatic compression devices: Intermittent pneumatic compression of the legs has shown efficacy in small randomised trials and is an option for patients who cannot tolerate medications.
• Cognitive Behavioural Therapy (CBT): CBT-I (CBT for insomnia) targets the sleep hyperarousal that perpetuates insomnia in RLS patients; it is an effective adjunct and may reduce reliance on sedating medications.
• Review and reduce culprit medications: Discontinuing or substituting antihistamines, dopamine antagonists, or SSRIs can produce rapid and significant improvement without adding new drugs.
• Transcutaneous electrical nerve stimulation (TENS): Some patients report symptomatic benefit; evidence is limited but it carries no adverse medication effects.